Antibiotic compositions for treating bacterial infections
AssigneesAgency for Science, Technology and Research, National University Hospital (Singapore) Pte Ltd
InventorsDesmond Heng, Sie Huey Lee, Jeanette Teo, Wai Kiong Ng, Reginald Tan
Life of this patent
Estimating the term…
Abstract
The present disclosure provides dry powder antibiotic compositions that are effective in the treatment of bacterial infections and associated conditions. Moreover, the present disclosure provides dry powder antibiotic compositions for the treatment of bacterial infections, by multi-drug resistant bacteria, resulting in the subsequent reduction in the prevalent rates of drug resistance.
Claims21
A process for manufacturing a medicament for treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium utilizing a dry powder inhaler (DPI) composition of antimicrobial agents comprising:
- a polymyxin antibiotic;
- and at least two further antibiotics selected from the group consisting of an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide, a lipopeptide, a macrolide, a monobactam, a nitrofuran, a oxazolidonone, a penicillin, a polypeptide, a quinolone, a sulfonamide, a tetracycline, a chloramphenicol, a phosphonic acid antibiotic and a mycobacteria antibiotic, wherein the antimicrobial agents are spray dried with a 5.5 μm spray mesh size, and have a particle size of between about 1 and 5 μm.
A process for manufacturing a medicament for treating a respiratory system infection by a bacterium utilizing a dry powder inhaler composition of antimicrobial agents comprising:
- a polymyxin antibiotic;
- and at least two further antibiotics selected from the group consisting of an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide, a lipopeptide, a macrolide, a monobactam, a nitrofuran, a oxazolidonone, a penicillin, a polypeptide, a quinolone, a sulfonamide, a tetracycline, a chloramphenicol, a phosphonic acid antibiotic and a mycobacteria antibiotic,
- wherein the antimicrobial agents are spray dried with a 5.5 μm spray mesh size, and have a particle size of between about 1 and 5 μm.
A process for manufacturing a medicament for treating a pulmonary disease or condition utilizing a dry powder inhaler composition of antimicrobial agents comprising:
- a polymyxin antibiotic;
- and at least two further antibiotics selected from the group consisting of an aminoglycoside, an ansamycin, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a lincosamide, a lipopeptide, a macrolide, a monobactam, a nitrofuran, a oxazolidonone, a penicillin, a polypeptide, a quinolone, a sulfonamide, a tetracycline, a chloramphenicol, a phosphonic acid antibiotic and a mycobacteria antibiotic,
- wherein the antimicrobial agents are spray dried with a 5.5 μm spray mesh size, and have a particle size of between about 1 and 5 μm.
Dependencies are inferred from the claim text.